Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease
- PMID: 3046811
- DOI: 10.1038/clpt.1988.147
Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease
Abstract
Theophylline disposition (5.5 mg/kg administered intravenously) was studied in 12 patients with cystic fibrosis (CF) and 16 healthy control volunteers. Dietary controls and logs were used to minimize the influence of food on theophylline metabolism. Control subjects were restudied in random order on two subsequent occasions after 2 weeks of either pancreatic enzymes or placebo. Theophylline and its three main metabolites, 1-methyluric acid, 3-methylxanthine, and 1,3-dimethyluric acid, were analyzed in serum and urine by HPLC. The total body clearance, renal clearance, nonrenal clearance, and volume of distribution of theophylline were significantly greater (p less than 0.05) in patients with CF than in control subjects. The increased nonrenal clearance was the result of increased biotransformation to each of the three main metabolites. Patients with CF exhibited enhanced N-demethylation and 8-hydroxylation of theophylline, pathways that appear to be mediated by two different families of P-450 enzymes. Theophylline clearance after 2 weeks of pancreatic enzyme administration in the control subjects was the same as with placebo. Possible reasons for enhanced theophylline biotransformation in CF are discussed.
Similar articles
-
Lack of effect of terfenadine on theophylline pharmacokinetics and metabolism in normal subjects.Br J Clin Pharmacol. 1989 Mar;27(3):391-5. doi: 10.1111/j.1365-2125.1989.tb05383.x. Br J Clin Pharmacol. 1989. PMID: 2497767 Free PMC article.
-
Theophylline pharmacokinetics in normal elderly subjects.Clin Pharmacol Ther. 1988 Nov;44(5):522-30. doi: 10.1038/clpt.1988.189. Clin Pharmacol Ther. 1988. PMID: 3180633
-
Mechanism of interaction between theophylline and mexiletine.DICP. 1991 Jul-Aug;25(7-8):727-30. doi: 10.1177/106002809102500704. DICP. 1991. PMID: 1949927
-
Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.Ann Pharmacother. 1993 Jan;27(1):74-9. doi: 10.1177/106002809302700117. Ann Pharmacother. 1993. PMID: 8431626 Review.
-
Pharmacokinetics of drugs in cystic fibrosis.Clin Rev Allergy. 1991 Spring-Summer;9(1-2):169-210. doi: 10.1007/978-1-4612-0475-6_11. Clin Rev Allergy. 1991. PMID: 1884324 Review.
Cited by
-
Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients.Br J Clin Pharmacol. 1995 Jan;39(1):85-9. doi: 10.1111/j.1365-2125.1995.tb04415.x. Br J Clin Pharmacol. 1995. PMID: 7756106 Free PMC article. Clinical Trial.
-
Linezolid pharmacokinetics in adult patients with cystic fibrosis.Antimicrob Agents Chemother. 2004 Jan;48(1):281-4. doi: 10.1128/AAC.48.1.281-284.2004. Antimicrob Agents Chemother. 2004. PMID: 14693551 Free PMC article. Clinical Trial.
-
Drug disposition in cystic fibrosis.Clin Pharmacokinet. 1998 Oct;35(4):313-29. doi: 10.2165/00003088-199835040-00004. Clin Pharmacokinet. 1998. PMID: 9812180 Review.
-
Enhanced drug metabolism in young children with cystic fibrosis.Arch Dis Child. 1997 Sep;77(3):239-41. doi: 10.1136/adc.77.3.239. Arch Dis Child. 1997. PMID: 9370904 Free PMC article.
-
Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.Br J Clin Pharmacol. 1995 Oct;40(4):319-24. doi: 10.1111/j.1365-2125.1995.tb04553.x. Br J Clin Pharmacol. 1995. PMID: 8554933 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical